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Background. The recent scale-up of antiretroviral therapy (ART) coverage in resource-limited settings has greatly improved 
access to treatment. However, increasing numbers of patients are failing first- and second-line ART. 
Objective. To examine factors affecting adherence to second-line ART from the perspective of clinic staff and patients, assessing 
both individual and structural perceived barriers. 
Methods. Research was conducted at a large primary care tuberculosis (TB)/HIV clinic in Khayelitsha, a peri-urban township 
in Cape Town, South Africa. Participants were drawn from a Médecins Sans Frontières-run programme to support patients 
failing second-line ART. A qualitative research approach was used, combining multiple methodologies including key informant 
interviews with staff (n=11), in-depth interviews with patients (n=10) and a Photovoice workshop (n=11). Responses and 
photographs were coded by content; data were transformed into variables and analysed accordingly.
Results. Staff identified drinking, non-disclosure, not using condoms and pill fatigue as barriers to ART adherence, while 
patients identified side-effects, not using condoms and a lack of understanding concerning medication timing. With respect 
to service delivery, staff identified a need for continued counselling and educational support following ART initiation. Patients 
were concerned about missing medical records and poor staff attitudes in the clinic. 
Conclusion. These findings identify discrepancies between provider and patient perceptions of barriers to, and facilitators of 
adherence, as well as of service delivery solutions. This highlights the need for on-going counselling and education following 
ART initiation, improved quality of counselling, and improved methods to identify and address specific barriers concerning 
medication adherence. 
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In 2010, the World Health Organization esti-
mated that 34 million people were living with 
HIV/AIDS (PLWHA) – of whom more than 30 
million were living in low- and middle-income 
countries.[1] Around 9.7 million were receiving 
antiretroviral therapy (ART) in 2012, more than a 30-fold 
increase in ten years.[2] With an increased number of people 
receiving ART, first- and second-line treatment failure has 
become more common.[1,3] 
Treatment failure results in increased morbidity and mor-
tality for PLWHA, with larger numbers requiring more ex pen-
sive second- and third-line treatment, and an increased risk of 
HIV transmission, including drug-resistant strains. [3] For ART 
to be effective, adherence rates must be between 90%[4,5] and 
95%.[6,7] Studies also indicate that many failures are the result 
of suboptimal adherence, rather than due to the development 
of antiretroviral (ARV) resistance, suggesting a potential for 
continued efficacy with improved adherence, especially on 
protease inhibitor (PI)-based regimens.[8-10]
Patients failing second-line regimens have no further treatment 
options available in the public sector in sub-Saharan Africa, as 
third-line regimens are too costly.[11] There is an escalating need 
to mitigate failure rates and improve the effectiveness of ART 
within existing public health structures.[12]
We sought to investigate: (i) major barriers to, and 
facilitators of ART adherence in this population; and (ii) 
areas of ART service delivery that shape patient behaviour. 
We examined the experiences of patients who failed both 
first- and second-line ART, identified through routine viral 
load (VL) testing. The most commonly cited barriers to 
adherence included: side-effects; regimen complexity; socio-
cultural factors such as complex dosing schedules, alcohol 
and substance abuse; economic factors; and patient-provider 
relationships.[13-17] No studies specifically addressing barriers 
to, or facilitators of adherence in patients with multiple 
episodes of treatment failure and re-adherence were identified. 
The majority of patients in this study achieved successful 
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work is needed to better understand the successful re-suppression of 
HIV in these patients.[8] 
Methods
Setting
This study was conducted at Ubuntu Clinic, a public sector primary care 
HIV/TB clinic in Khayelitsha, a peri-urban township in Cape Town, 
South Africa (SA). Khayelitsha, with more than 500 000 residents, has 
one of the highest burdens of HIV infection nationally and worldwide, 
with an antenatal HIV prevalence of >26% in 2010.[18] ARVs have been 
available since 2001 and currently there are more than 20 000 PLWHA 
in the area receiving ART. [19] Ubuntu Clinic serves the biggest and oldest 
cohort of ART patients in Khayelitsha. By the end of 2011, 6 296 patients 
were receiving ART, of whom 463 (7.4%) were receiving second-line 
treatment. Currently, 20 new patients per month are starting second-
line ART.[18]
Treatment success is assessed through VL testing. Provincial guide-
lines recommend that a VL test is performed at four and 12 months 
after treatment initiation and on a yearly basis thereafter.[11] After an 
initial high VL (defined as >1 000 copies/ml), patients attend adherence 
counselling and a follow-up VL is taken three months thereafter. Two 
consecutives VLs >1 000 copies/ml confirm virological failure, after 
which patients should be switched to a second-line ART regimen. At 
Ubuntu Clinic, after five years of receiving ART, an estimated 14% of 
patients experienced virological failure and 12% were switched to a 
second-line regimen.[20,21] Previous studies have found second-line failure 
rates in SA to be as high as 33%[22] and 40%,[25] respectively. The latter 
study conducted viral genotyping at Ubuntu Clinic and found that only 
two of 37 second-line failure patients had developed drug resistance.[23] 
Médecins Sans Frontières (MSF) is an international non-governmental 
organisation that has worked closely with the Western Cape Department 
of Health during the scale-up of ART coverage in Khayelitsha. In 
2010, MSF, in collaboration with Ubuntu Clinic staff, developed and 
implemented a patient-centred model of care for patients failing second-
line ART. The programme provides a dedicated space, and individual and 
group counselling support. At the time of this study (August 2011), 49 
patients were enrolled in the second-line failure clinic. This population 
allowed a first look at a small, but growing group of patients with multiple 
treatment failures in a setting with one of the highest HIV burdens 
worldwide. 
Study population
Patients in MSF’s second-line failure programme (patients with at least 
one VL >1 000 copies/ml) were approached to participate in the study. 
Of the 49 patients meeting these criteria, 12 were included based on 
availability and willingness to participate. Nurses, counsellors and 
doctors were selected from both the MSF programme and Ubuntu 
Clinic staff as key informants; they were purposively sampled to include 
those with the most exposure to patients receiving second-line ART. 
Data collection
This study used multiple methods including in-depth patient and key 
informant interviews and a Photovoice workshop.[24] Semi-structured 
interviews were developed with input from all co-investigators on 
the project. Key informant interviews focused on staff perspectives 
regarding reasons for treatment failure and barriers in healthcare 
delivery. Patient interviews focused on individual reasons for treatment 
failure and perceptions of clinic service delivery. 
Patients also engaged in a Photovoice workshop, a participatory 
quali tative research method where participants are given disposable 
cameras to take photographs of predetermined themes, and then en -
gage with each other around the meanings and experiences behind 
the photographs.[24] Participants took part in two day-long workshops. 
The first introduced Photovoice and, with the participants, developed 
themes to explore the relationship between treatment and the people, 
places and ideas in their daily lives. Participants were then given two 
weeks to take photographs and return the cameras to the research team 
for development. In the second workshop, participants chose three of 
their photographs to share, and researchers facilitated discussion and 
the identification of themes. Twelve patients consented to be in the 
study, all took part in the Photovoice workshop; however, two could not 
be found for in-depth interviews following multiple attempts. One had 
relocated from the area, and another could not be located. 
Data analysis
Interviews were conducted in English (n=3) and isiXhosa (n=7), de-
pend ing on participant preference, with the aid of a translator. Inter-
views and Photovoice sessions were tape-recorded and transcribed; each 
was conducted by one of two separate investigators. Interview content 
and photographs were analysed to identify recurring themes. The initial 
analysis was done by a single investigator, and the review of themes 
identified was performed by all co-investigators. A process of coding 
and categorisation of data content assisted in bringing meaning to the 
responses and photographs.[25,26] Data were transformed into variables, 
with interviews and Photovoice data analysed separately. 
Ethical approval
The study was approved by the Human Research Ethics Committee and 
Institutional Review Board of the Faculty of Health Sciences, University of 
Cape Town. Each participant gave written consent for their involvement 
in the study, including consent to publication of their photographs.
Results
Sample characteristics
Of the 10 patients interviewed, nine were female and one was male. All 
lived in Khayelitsha. The patients received first-line ART for a mean of 
32 months (range 13 - 63) and second-line ART for a mean of 38 months 
(range 10 - 72). After being switched to second-line ART, patients 
experienced their first elevated VL (>1 000 copies/ml) at a mean of 12 
months (range 4 - 41). Of the 11 key informant interviews, three were 
nurses, four were counsellors and four were doctors. Staff had worked a 
mean of 66 months (range 6 - 168) in the clinic. 
Barriers and enablers to adherence
Patient-cited barriers
No patient responded that a single barrier caused their treatment failure 
and the majority (n=6) stated that they had made an active decision to stop 
taking their medication due to the barriers identified. The top reasons for 
ART failure (each cited by 3 patients) were side-effects, not using condoms, 
a lack of understanding around medication timing, didanosine (DDI) time 
delay between medication and food intake, and large pill size (Table 1).
Key-informant-cited barriers
The main adherence barriers cited by staff were patient drinking (n=9), 
non-disclosure (n=8), not using condoms (n=6), pill fatigue (n=5) and 
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Side-effects
One-third of patients identified side-effects as 
a reason for treatment failure, citing nausea, 
vomiting, stomach pains and cramping: ‘I 
have this diarrhoea in my stomach and it’s 
cramping … it started my viral to go up and up 
and up because I skip now because I’m scared 
that maybe I’m going to the church and my 
stomach maybe want to run.’ (P06) 
‘Patients are not taking three of the tablets, 
taking two because one has got side-effects.’ 
(KI02)
Another patient on second-line ART stopped 
because she did not realise her VL would go up 
quickly and was surprised when it became 
detectable. One-third of key informants also 
identified side-effects as a barrier. 
Not condomising
One-third of patients blamed their failure on 
not using condoms: ‘I had a boyfriend and 
didn’t condomise with the boyfriend. After 
that I … failed and was changed to second-
line.’ (P04)
Not using condoms also emerged as a central 
theme in the key informant interviews, with 
six of 11 respondents citing it as a reason for 
non-adherence. Key informants did appear 
to understand this risk to treatment success 
as a consequence of transmission of resistant 
strains. However, they seemed to inflate the 
risk of this occurring. One key informant 
described a tendency of staff to defer to an 
‘easy’ explanation for treatment failure. 
Timing of medication
At the time of ART initiation, counsellors 
instructed patients to take their pills twice 
daily at exactly the same time in the morning 
and evening. This is laid out as one of the 
‘rules’ of ART adherence and is presented in 
a concrete format, allowing very little scope 
for the patients when times clashed with their 
schedules: ‘To keep the time is too difficult. I 
take my pills at 7 but sometimes wake up at 8 
and the time has passed.’ (P05)
One patient (P04) stated that she often 
missed doses because of her work schedule. 
Another blamed his counsellor for not telling 
him to take his medication twice daily, e.g. at 
07h00 and 19h00. One-third of patients indi-
cated that they had defaulted on first-line ART 
due to such strict parameters: ‘Before they 
said to us, if you used to take your tablets at 8 
o’clock in the morning or night you can’t take 
it at 9 o’clock because it’s too late. But [MSF 
counsellors] said it’s not late, you must take the 
tablets. If you forget, maybe it’s two hours or 
one hour, you can take your tablets.’ (P02)
Many patients cited this increased latitude 
around timing as helpful to becoming re- 
adherent, allowing them more freedom to 
adjust timing around their schedules. Only 
one key informant mentioned timing of 
medication as a barrier to patient adherence. 
DDI time delay
Until 2009, SA guidelines recom mended DDI 
as part of its second-line ART regimen. This 
required patients to take the medication 
one hour before eating. This time-delay was 
identified by one-third of patients and one key 
informant as a reason for treatment failure.
‘You must leave [medication] for the hour 
and then you forget to take other tablets after 
that. You take it maybe at 6 o’clock; you have to 
run at 7 o’clock for the train … You think okay 
that time is past, so you have to drink at night. 
That’s why your viral load is so grown.’ (P06)
‘We picked up that they were having the 
problem with the DDI delay and for getting.’ 
(KI01)
Pills too large
One-third of patients stated that they had 
difficulty taking their medication because 
of the large pill size. Two of these patients 
discontinued taking their second-line regimen 
for this reason: ‘It was getting so difficult to 
take second-line. It was a big pill and I decided 
to stop.’ (P04)
Pill size was not noted in the key informant 
interviews as a reason for non-adherence.
Patient drinking
One patient identified drinking as a factor in 
her treatment failure. In the key informant 
interviews, however, alcohol use emerged as 
the most cited reason for failure (cited by 9). 
Staff said that this affected adherence in two 
ways: Firstly, patients often forget to take their 
medication when drinking. Secondly, staff 
reported that, as with the timing of medication, 
patients understood that they could not drink 
and take their ARVs literally and stopped 
treatment altogether: ‘[The patient] sees that he 
Table 1. Barriers to ART adherence cited patients and key informants
Issue





Drinking 9 (82) 1 (10)
Disclosure 8 (73) 1 (10)
Not condomising 6 (55) 3 (30)
Pill fatigue 5 (45) 1 (10)
Forgetting 5 (45) 2 (20)
Patients not honest with clinic staff 3 (27) -
Stigma 3 (27) -
Side-effects 3 (27) 3 (30)
Lack of food in the home 2 (18) -
Life stress 2 (18) 2 (20)
Insufficient support 2 (18) -
Treatment partner not working 1 (9) -
Didanosine/one-hour delay* 1 (9) 3 (30)
Denial 1 (9) -
Feeling better 1 (9) -
Embarrassed about defaulting 1 (9) -
Timing of medication 1 (9) 3 (30)
Staff shouting 1 (9) -
Gave up - 1 (10)
Has not accepted HIV status - 1 (10)
Unable to keep appointment - 1 (10)
Pills too large - 3 (30)
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is much better and he will start to drink again. It’s whereby most of them 
are failing because when they are drinking, they don’t take their medication, 
they stop their medication.’ (KI02)
Non-disclosure
One patient identified non-disclosure as a barrier, citing the difficulty 
of maintaining ART without support at home where she felt she had to 
hide her medication: ‘Some of them they don’t tell their partners that 
they are positive and are on treatment. They need to disclose to friends, 
to partners.’ (KI10)
Eight of the 11 key informants indicated that non-disclosure 
was problem atic. Many of their patients felt the need to hide their 
medication and would often not take it when travelling or if others were 
present at work or at home. 
Pill fatigue
One patient identified pill fatigue as a reason for defaulting, noting: ‘I 
just keep getting tired sometimes. To take treatment everyday is not 
nice.’ (P03); ‘Second-line patients are more likely to have problems 
because of pill fatigue.’ (KI09)
Five of the 11 key informants identified pill fatigue as a barrier. 
Forgetting
Five of the 11 key informants identified patients forgetting to take their 
pills as a barrier. This was often cited with various reasons, ranging from 
patients being busy with work or family obligations, travelling without 
medication, and the lack of a plan for treatment adherence (alarm or 
friend/family to remind them). 
Two of 10 patients identified forgetting as a barrier. 
Service delivery barriers
Patient-cited clinic obstacles
Interviews with patients revealed difficulties with healthcare delivery 
at Ubuntu Clinic, with some patients citing missing medical records 
(n=6) and clinic staff shouting at patients (n=6). Few, however, cited 
these problems in response to questions on defaulting or suboptimal 
adherence. Rather, many seemed to view them as an expected part of 
clinic attendance; two patients stated that clinic problems affected their 
adherence or their attendance at the clinic: ‘Sometimes they will shout 
you if you ask something … shouting at the top of their voices. You feel 
not happy and you go home and feel unhappy. And next time you say 
I’m not going to this clinic anymore.’ (P02)
Key-informant-cited clinic obstacles
Staff identified a lack of continued counselling support following ART 
initiation (n=8) and insufficient education for patients (n=3) as key obsta-
cles. One counsellor noted: ‘The point where we are failing is to really find 
out exactly why [the patient] is failing and try to fix the thing that makes 
them to fail first-line … there is no time to focus on the problem, instead we 
are just providing the medication without support.’ (KI09)
Staff also highlighted the need for increased follow-up to catch 
adherence issues earlier on. One clinician identified counselling as a 
critical but under-utilised component: ‘There is so much pressure for 
roll-out of getting more patients onto ARVs, getting nurses dishing out 
ARVs … counsellors are being overlooked but they are a critical part of 
the whole process.’ (KI08)
Three of the 11 key informants responded that there was no need for 
improvement and seven did not think that the clinic needed more time 
or resources for patients. These staff felt that patients should engage 
better with the healthcare system, that many obstacles faced by patients 
are difficult for the clinic to solve, or that current resources could be 
managed better. 
Patient perspectives on the MSF programme
Patients cited feeling more comfortable and free to share problems 
(n=7), shorter wait times (n=6), seeing the same staff (n=4) and support 
groups (n=2) as reasons why they preferred MSF’s programme to the 
larger clinic: ‘I feel free now that on this side of the clinic. I can share 
everything … when I come here I feel at home because before when I 
was taking medicine on that side [larger clinic], I was afraid whether I 
had done right or done wrong.’ (P04)
A more patient-centred environment enabled more open discussion 
of barriers to adherence and facilitated the resolution of issues. 
Fig. 1. The daughter of a patient reminds her mother to take her medication.
Fig. 2. A counsellor explaining medication parameters to a patient.
Fig. 3. A patient who struggled with an alcohol abuse problem depicts herself 
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Photovoice patient perspectives 
The Photovoice component of the study elicit-
ed a different patient perspective on treatment 
compared with the interviews. The photographs 
and the workshop discussion became a plat-
form for sharing successes and sources of 
strength. Each patient chose three pictures 
to share (Table 2). Of 33 total photographs 
shared, only nine illustrated negative aspects of 
patients’ lives, such as poor living conditions, 
difficulty remembering treat ment, poor clinic 
service and not having family support. Yet, 
when presented by patients, these negative 
aspects were often treated as barriers overcome 
or obstacles to get past. 
The remaining photographs (24/33) showed 
supportive family and friends (n=11) (Fig. 1), 
the importance of treatment (n=5), gratitude 
towards the MSF clinic staff (n=3) (Fig. 2), 
religion as a source of strength (n=2), and 
over coming drinking problems (n=2) (Fig. 
3). There was a notable difference in the 
themes presented by patients as part of the 
Photovoice analysis and those that emerged 
in the interviews. This is likely due to the 
difference in methodology and format. Photo-
voice involved individual presentation to the 
full group; patients seemed to experience this 
format as a type of support group with a 
focus on sharing positive experiences, often to 
encourage others in the group by describing 
facilitators to adherence and sources of support: 
‘I believe in tablets, because it’s my life and I 
will be taking treatment for life. Not for me, 
but for the kids too.’ (P04)
Discussion
South Africa’s National Strategic Plan on 
HIV, STIs and TB: 2012 - 2016 calls for 80% 
of PLWHA to be receiving ART by 2016,[27] 
expanding from the 56% of those eligible 
who were receiving ART in 2009.[28] However, 
this focus on initiating patients on treatment 
has largely ignored the rising numbers of 
patients failing treatment.[11,29] We aimed to 
identify barriers and facilitators to long-term 
ART adherence in the context of second-line 
treatment failure from the perspective of staff 
and patients. 
Interview themes most frequently identified 
as barriers to treatment adherence differed 
between patients and staff. Staff identified 
drinking, non-disclosure, not using condoms, 
pill fatigue and forgetting to take medication 
as barriers to adherence, while patients identi-
fied side-effects, not using condoms and a 
lack of understanding around medication 
timing. With respect to service delivery, staff 
identified a need for continued counselling 
and educational support following ART 
initiation. Patients were concerned about 
missing medical records and poor staff 
attitudes in the clinic. 
Patients as well as staff had a tendency 
to blame treatment failure on factors that 
were external to themselves and their role 
in treatment adherence. This is consistent 
with previous findings in a similar setting, 
where ART patients who adhered tended 
to ascribe this to internal strength, whereas 
when they failed, external factors were 
identified.[30] In the current study, the princi-
pal patient-identified barriers were side-
effects, not condomising, DDI, large pills 
and not understanding medi cation – all but 
condomising point toward obstacles external 
to the patient; whereas, staff identified patient 
drinking, not disclosing, not condomising 
and pill fatigue most frequently – all of which 
focus more on patient behaviour. 
In the principal obstacles identified, the only 
one common to both patients and staff was not 
using a condom. When staff were questioned 
further on this topic, it became clear that they 
seemed to understand not condomising as 
contributing to the spread of resistant HIV 
strains within the population. However, given 
the small numbers of those failing second-
line ART, the likelihood was very low of any 
patients in this sample contracting a resistant 
strain rather than failure resulting from non-
adherence. Given the complexities involved 
in identifying behaviours that contribute to 
non-adherence, one explanation is that both 
patients and staff found not condomising a 
factor that is easily identifiable and relatively 
easily addressed, causing both to over-
emphasise its role. This over-emphasis adds 
to the knowledge gap patients experience 
in understanding the reasons for treatment 
failure, reducing their ability to address and 
identify actual adherence issues.
For some patients, ART failure resulted 
from a lack of understanding around the 
parameters of their medication. For others, the 
issues were psychosocial in nature, involving 
bad living environments or a lack of support 
at home. Yet, some patients made an active 
decision to stop taking medication and 
became re-adherent when issues such as side-
effects, pill size or time delay were addressed. 
Patients enrolled in the second-line failure 
clinic receive patient-centred support with 
individual and group counselling. Unpublished 
data show a high VL re-suppression rate 
among those enrolled in the programme. 
This is likely due to improved access to staff, 
continuity of staff and more supportive clinic 
environment, allowing for quicker follow-up 
and more open discussion of issues affecting 
adherence. This is consistent with findings 
from similar studies where strong and open 
relationships between patients and healthcare 
providers facilitate adherence.[30] 
There is currently an information gap 
between patients experiencing difficulties 
with treatment and clinic staff addressing 
those issues. There are personal and structural 
reasons for this, stemming from patients not 
informing staff when experiencing difficulties, 
not understanding which behaviours will lead 
to raised VLs and not feeling comfortable 
with staff. The most patient-cited clinic 
obstacle was staff shouting at patients; 
however, some patients also highlighted the 
benefit of feeling open and able to share 
their issues with the MSF programme staff. 
This serves to emphasise the importance of 
trust and communication be tween patients 
and staff, particularly between patients 
and counsellors; patients’ difficulties with 
treatment remained unresolved until the 
clinic environment changed, allowing for 
open discussion and management of those 
issues. Though previous research has shown 
similar barriers to adherence including 
poor patient-staff relationships, untimely 
addressing of adherence issues and inadequate 
counselling following initiation of ART,[31] 
the patient population in this study showed 
that improving these issues within service 
delivery can lead to improved adherence and 
VL suppression. 
Many staff responded that there was no 
need for an improvement in service delivery 
and that the clinic had sufficient resources 
Table 2. Frequency of themes of 
photographs shared on patients’ 
perspectives of ART adherence
Main photo theme n
Support of family/friends 12
Importance of treatment in lives 5
Gratitude towards MSF staff 3
Difficulty of treatment 3
Religion as a source of strength 2
Overcoming a drinking problem 2
Poor living environment 2
Food insecurity 1
Regret for losing previous wealth 1
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to serve its patient population, highlighting a tendency among some 
staff not to be critical of the status quo or look for methods to 
improve current service delivery. The present focus on increasing ART 
coverage and the relatively few patients who are failing treatment has 
concentrated efforts to increase the number of patients receiving ART, 
leaving little time to focus on the increasing rate of ART failure. 
Study limitations
Interviews conducted in isiXhosa were translated during the interview 
in real time by MSF staff, which may have influenced patient response, 
either limiting patient openness due to the presence of clinic staff or 
limiting the interviewer interaction because of the language barrier. The 
high proportion of female respondents limited the generalisability of 
the study findings, suggesting that our results may only be appropriate 
to a female population failing second-line ART. Though the proportion 
of females attending the second-line ART clinic at the time was 68%, 
participation of males was low due to difficult schedules and willingness 
to participate. Only one male participated in the study, making it 
difficult to determine whether responses were gender-biased. The study 
population comprised a small group of patients who had a very specific 
context of care delivery within a programme separate from standard 
government clinical care. Thus, their experiences within a more ade-
quately resourced environment than public clinical care is certain to 
have affected their perspectives on service delivery as well as their high 
level of re-adherence. Moreover, because of the relatively low numbers 
of patients failing second-line ART, the large bulk of staff experience is 
with patients receiving first-line ART. As the number of patients failing 
second-line ART increases, so will staff experience with these patients, 
offering a future opportunity to assess staff perspectives on barriers to, 
and facilitators of adherence. 
Study significance 
This study focused on a patient population that included among the 
first patients in SA who have experienced virological failure on second-
line ART medication. Yet, many of these patients have been able to 
suppress their VLs within the MSF-run programme. This success 
highlights the importance of both counsellors and clinicians providing 
the necessary patient support – to ensure that patients are adequately 
equipped to initiate ART successfully and to serve as the front line for 
identifying problems as they arise. Many of the patients who became re-
adherent benefitted from open relationships with clinic staff, enabling 
discussion and management of adherence issues. Prioritising patient-
staff relationships and strengthening support mechanisms to identify 
adherence issues early on offers an opportunity for the current system 
of ART initiation and support to improve patient outcomes. The largely 
positive themes elicited by Photovoice illustrate that many multiple-
failure patients feel positively about their treatment and lives and, 
with improved support mechanisms, this can translate into improved 
adherence and outcomes. Although some patients did make an active 
decision to stop taking ART, all continued to attend the clinic and 
engage with the healthcare system, demonstrating an opportunity 
for clinic staff to reduce failure rates in a patient population with no 
treatment option following failure of a second-line ART regimen. 
Recommendations
The frequency with which not using condoms was cited as a factor 
contributing to ART failure should be examined further at the staff 
and patient level to ensure that messaging is not misleading and that 
patients address all behaviours affecting adherence. Continued follow-
up, especially with regards to easily altered behaviour or misunderstood 
medication parameters (e.g. timing, missed doses, forgetting) should 
be explored to identify how best to equip patients for ART regimens. 
Continuity of care and patients’ comfort with staff is another area 
that could be explored to identify whether and how that may have 
contributed to improved patient outcomes in this group. Though few 
patients were found to have resistant HIV strains following genotyping 
at Ubuntu Clinic, the incidence of primary or secondary infection 
with resistant strains should be explored. This is likely to become an 
increasingly important aspect of ART failure as the prevalence of 
resistant strains increases.
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